---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-006495"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2025-01-17T23:59:59+00:00"
generated_at: "2026-05-27T23:12:46.210919+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharmaceuticals CCO Christopher Von Seggern departs; consulting agreement through May 2025

## Summary
- Christopher Von Seggern ceased as Chief Commercial Officer on January 17, 2025.
- Separation Agreement provides severance per 2020 offer letter and 2024 annual bonus.
- Consulting Agreement through May 1, 2025; equity awards continue vesting until then.
- No replacement named for the CCO role.

## SEC filing metadata
- accession: 0000950170-25-006495
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2025-01-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017025006495/0000950170-25-006495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017025006495/xene-20250117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-006495
- JSON: https://secwatch.observer/filing/0000950170-25-006495.json
- Plain text: https://secwatch.observer/filing/0000950170-25-006495.txt

## Key facts
- Executive change
  Christopher Von Seggern departed as Chief Commercial Officer at Xenon Pharmaceuticals Inc..
  - Action: ceased
  - Role: Chief Commercial Officer
  source text: On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the “Company”) and departed the Company as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017025006495/0000950170-25-006495-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.